The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of carboplatin (C) and bevacizumab (BEV) in patients (pts) with breast cancer brain metastases (BCBM).
Nancy U. Lin
Consultant or Advisory Role - Geron (U); GlaxoSmithKline; Novartis; to-BBB technologies BV (U)
Research Funding - Bayer; Genentech; Geron; GlaxoSmithKline; Novartis
Rebecca Sue Gelman
No relevant relationships to disclose
W. Jerry Younger
No relevant relationships to disclose
Jessica Sohl
No relevant relationships to disclose
Rachel A. Freedman
Research Funding - Puma Biotechnology
A. Gregory Sorensen
No relevant relationships to disclose
Elizabeth Bullitt
No relevant relationships to disclose
Gordon J Harris
No relevant relationships to disclose
Daniel Morganstern
No relevant relationships to disclose
Bryan P. Schneider
Consultant or Advisory Role - Genentech
Ian E. Krop
Research Funding - Genentech
Eric P. Winer
No relevant relationships to disclose